De’ Longhi Group: a Quarter of Robust Revenue Growth of 8.4% and Solid Margin Expansion Drives an Upward Guidance Revision Business Wire Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution
Titan Group: First Half 2026 Results Business Wire Strong sales performance with continued margin expansion, while accelerating the integration of new acquisitions
Fluidra Delivers a Strong First Half of 2026 and Maintains Positive Momentum in a Dynamic Environment Business Wire Sales increased by 5% at constant FX to €1,258 million, driven by Fluidra’s customer focus and consistent execution Adjusted EBITDA grew by 6% at constant FX to €321 million, supported by firm cost discipline The company signed an agreement to acquire Hydrapro, a French manufacturer specializing in water treatment, to further support its growth Fluidra launches a €40 million share buy-back program and maintains full-year guidance
Airspan Delivers Revenue Growth and Profitability in First Half 2026 July 27, 2026 Revenue growth and a strong financial foundation
Almirall H1 2026 Results July 24, 2026 Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution. The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth. Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets. The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM). Almirall advances its innovation strategy through progress across its R&D pipeline, including four ongoing PoC/Phase II studies and two additional PoC studies planned to be initiated by end of 2026, targeting five dermatological diseases. The first readouts are expected towards the end of 2026. Almirall signs a strategic research collaboration and licensing agreement with Certest Biotec to discover and develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions. Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA.
GRIDSERVE Reports 45% YoY Growth, as UK’s Most-Used Charging Network Proves the Commercial Case for EV Infrastructure at Scale June 19, 2026 GRIDSERVE's national charging network generated £64 million in revenue in 2025, with utilisation increasing across the network The business also reached positive EBITDA for the first time, delivering group EBITDA of £3 million and EBITDA of £26 million on its charging network Milestone reached under new CEO Daniel Kunkel, who joined in March 2025, bringing renewed strategic focus to the core charging business More than three million charging sessions were completed in 2025, driven by growing demand for reliable, convenient charging and GRIDSERVE’s award-winning customer experience
Lone Star Funds Completes Sale of Xella to Holcim June 19, 2026 Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund X, L.P. has completed the sale of Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. Xella is a provider of efficient and sustainable walling solutions for the entire house shell. Through its [...]
£4.5bn black market cigarette tax loss should be ‘a major wake-up call’ for Labour June 4, 2026 Over half of cigarettes smoked in the UK are black market and are contributing £4.5bn to the country’s tax losses – a record high – according to new analysis from KPMG and tobacco giant Philip Morris. The findings show that 1.5bn more black-market, tax-free cigarettes were consumed by UK smokers last year compared to 2024, [...]
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2026 May 15, 2026 All economic and financial indicators grew: Consolidated revenues of €645.0 million (€607.5 million in 2025); EBITDA of €112.0 million (€105.3 million in 2025); EBIT of €95.1 million (€88.7 million in 2025); Profit before tax amounts to €99.8 million (€86.9 million in 2025).
Mr Kipling’s ‘biggest ever year’ bakes in sweet-looking profit at Premier Foods May 14, 2026 The owner of some of the UK’s best loved and most famous food brands hailed standout performer Mr Kipling, on Thursday which helped Premier Foods eat City profit forecasts for lunch. Mr Kipling – the brand behind the “exceedingly good cakes” tagline, in use continually since 1967, when the range made its debut – had its [...]